Biobanking, Cancer Biomarkers, and Clinical Trial Lab Services Markets Expand Through 2035

The global biobanking market is poised for significant expansion through 2035, driven by rising demand for precision medicine, increasing genomic research, expanding clinical trials, and growing investments in advanced life sciences infrastructure. Parallel growth is occurring in cancer biomarker testing and clinical trial central laboratory services, reflecting a broader transformation in how biological samples and diagnostic data support drug development and personalized treatment approaches.

Biobanking—the process of collecting, processing, storing, and distributing biological samples such as blood, tissues, DNA, RNA, and cells—has become a foundational pillar of modern biomedical research. As healthcare shifts toward personalized treatment approaches, high-quality biospecimen storage and data integration are becoming mission-critical for pharmaceutical companies, research institutions, and healthcare providers. Biobanks are no longer simple storage facilities—they are becoming integrated data ecosystems combining biospecimens, genomic data, and digital health records to enable faster therapeutic innovation.

The biobanking market is experiencing strong growth momentum due to increasing global research activity and the rising importance of biomarker discovery, regenerative medicine, and translational research. Key growth drivers include expansion of precision medicine initiatives, rising prevalence of chronic and genetic diseases, growth in genomics and proteomics research, increasing number of clinical trials globally, government and private funding for life sciences research, and advancements in cryopreservation and automation technologies.

Cancer biomarkers are measurable biological molecules or genetic alterations that provide insight into the presence or progression of cancer. These indicators are detected through blood, urine, tissue, or other bodily samples and serve multiple clinical purposes including screening, diagnosis, prognosis, treatment selection, and recurrence monitoring. As oncology moves toward personalized medicine, biomarker testing has become a foundational component of clinical decision-making.

The Cancer Biomarkers Market encompasses a wide range of products and services including reagents, assay kits, diagnostic instruments, bioinformatics software, and laboratory testing services. Biomarkers may be categorized into genomic biomarkers, proteomic biomarkers, epigenetic biomarkers, imaging biomarkers, and metabolomic markers. Among these, genomic biomarkers have witnessed rapid adoption due to advancements in sequencing technologies and declining testing costs.

Key diagnostic technologies supporting biomarker testing include polymerase chain reaction (PCR), immunoassays, next-generation sequencing, microarrays, and mass spectrometry. Liquid biopsy testing has emerged as one of the fastest-growing segments because it allows continuous monitoring of tumor evolution without invasive surgical procedures. Cancer biomarkers are widely used across multiple cancer types including lung cancer, breast cancer, colorectal cancer, prostate cancer, and melanoma. Lung cancer biomarker testing has gained significant traction with the increasing use of targeted therapies that rely on mutation identification.

The global clinical trial central lab services market is anticipated to expand at a CAGR of approximately 7% over the forecast period. Growth is primarily fueled by the increasing volume of clinical trials worldwide, rising R&D investments by pharmaceutical and biotechnology companies, greater adoption of biomarker-driven testing, advances in genomic and molecular diagnostics, and the growing integration of digital technologies into trial workflows.

Central lab services encompass specialized laboratory operations that support clinical studies by performing standardized testing and analysis of biological samples collected from multiple investigative sites. In contrast to local laboratories, central labs operate within a unified infrastructure that ensures harmonized sample management, high-quality testing procedures, and consistent, regulatory-compliant data generation across global studies. They play a critical role throughout Phases I–IV of drug development, conducting evaluations such as safety and efficacy testing, pharmacokinetics (PK), pharmacodynamics (PD), biomarker assessments, and genomic profiling.

Pharmaceutical sponsors, contract research organizations (CROs), and biotechnology firms depend on central laboratories to streamline trial operations and maintain standardized testing protocols across geographically diverse sites. Core service offerings include clinical chemistry, hematology, microbiology, immunology, pathology, and molecular diagnostics. Increasingly, advanced technologies—such as next-generation sequencing (NGS), liquid biopsy platforms, and high-throughput biomarker analysis—are being integrated into central lab workflows to support precision medicine initiatives, particularly in oncology and rare disease research.

According to data published by the NIH, more than 500,000 clinical studies had been registered on ClinicalTrials.gov worldwide as of April 2025. Within this evolving landscape, central laboratory services are essential for coordinating sample logistics, ensuring data harmonization, and delivering timely test results across numerous trial sites. Central labs provide consistent analytical support ranging from routine safety testing to advanced biomarker and genomic analyses, enabling sponsors to uphold scientific rigor while meeting diverse regulatory requirements.

Hospitals, diagnostic laboratories, academic research institutions, and pharmaceutical companies represent the primary end users across these markets. Hospitals increasingly adopt biomarker testing to guide therapy selection, while pharmaceutical companies leverage biomarkers during drug development to stratify patient populations. Pharmaceutical and biotechnology companies represent a major end-user segment for biobanking due to increasing reliance on high-quality biospecimens for preclinical and clinical research.

Technological innovation remains central to market expansion across all three segments. Key technological advancements include automated sample handling systems, advanced cryogenic storage solutions, cloud-based biobank information management systems (BIMS), AI-driven data analytics integration, and blockchain for data security and traceability. Automation reduces human error, enhances sample integrity, and improves operational efficiency critical for large-scale genomic studies and clinical research.

The clinical trial ecosystem is undergoing significant transformation as decentralized and hybrid models become increasingly prevalent. These approaches allow participants to engage remotely through telemedicine platforms, digital health technologies, and home-based sample collection kits. Consequently, central lab providers are enhancing their service portfolios to support remote logistics, advanced sample handling systems, and real-time data integration. Hybrid models help reduce patient burden, improve recruitment and retention, and expand access to diverse populations, thereby increasing trial inclusivity and efficiency.

North America holds a leading share in the biobanking market due to advanced research infrastructure, high healthcare expenditure, strong presence of biotech and pharmaceutical companies, and government-backed genomic initiatives. The Asia-Pacific region is witnessing rapid growth supported by expanding biotechnology sectors in China, Japan, and India, increasing public-private research collaborations, growing clinical trial outsourcing, and government-led precision medicine initiatives. Europe also maintains a strong position, driven by regulatory frameworks supporting ethical biobanking and cross-border research collaborations.

Increasing healthcare expenditure globally also contributes to biomarker adoption. Governments and insurers recognize that early cancer detection reduces long-term treatment costs and improves survival outcomes. Screening programs supported by biomarker-based diagnostics are becoming more common in developed healthcare systems. Additionally, partnerships between diagnostics manufacturers and pharmaceutical developers are accelerating companion diagnostic approvals. These collaborations ensure that biomarker tests are available alongside targeted therapies at the time of drug launch.

Despite robust growth prospects, the industry faces several challenges including ethical and regulatory compliance complexities, high infrastructure and operational costs, data privacy and consent management concerns, and standardization issues across international biobanks. High testing costs remain a significant barrier in developing regions. Advanced genomic testing infrastructure requires expensive equipment and specialized expertise. Reimbursement limitations in certain healthcare systems also restrict widespread adoption.